Excellent post Beta. I believe the dosing trial results is the necessary component as to which direction Chan goes with the financial strategy. If the trial is very compelling, this current LPC arrangement may be currently far more palatable. Hopefully, to buy a little extra time for a stronger negotiating position(partner) later in the year.
Oops wrong board. Last 30 days....ISIS UP 10%.....Vicl DOWN 20% The graph can always be your friend.
I do feel for our canine counterparts who will suffer an economic/employment loss, my heart goes out to them. However, on the brighter side, they will be able to spend more time with their families.
Oh, annd Number 11......Made in the USA!!
Strange how this is an issue with the Marines but not the Army. The Marines are always trying to one-up the other military divisions : ) All in fun...nephew in Marines and son in Army.
You have obviously received thumbs up for a reason. I am hoping for a miracle. The only hope I have, is that in 18 months we have a device that can serve a multibillion dollar and growing diabetes industry. I REALLY hope the device is far more effective than the incompetent humans trying to get it to the market... and patients.
That happens all the time in biotech....the e-mail list is exhaustive...still a doesn't hurt though.
Historically, the short term pps effect of this is not always predictable. However, the next 3 to 6 months will be a huge positive for CUR, especially with the number of catalysts due. Exposure is on our side. GLTA
Unfortunately, we remain focused on the Army contract as the sole source of progress and worse yet, maybe survival. The rest of the world can use NEPH products, I would really hope nongovernmental entities would purchase also...
Annieg007, I was the one who gave you the thumbs up and hope this continues to 20 plus. I will check out TSRS, but have to admit, as a long time biotech investor, your TSRS block buster with NO downside risk comment, reduced your credibility a notch or two. Again, I will check TSRS out, you sound genuine, but come on....
ISIS has 20 shots on goal....VICL Possibly ONE!! The company is a binary bet....not an investment...big difference.
Your argument contains merit. However, this next step involves AA SUBMISSION....not actual approval. Your arguments seem to forget that critical first step, which still gives the FDA a lot of wiggle room.
Keep cherry picking....AND if we would have sold VICL at 5.20 and bought ISIS at 6.80....where would we be?
Mid 2011...the chart can be anyones friend.
Didn't mean to be impolite. However,think about it, if we would have left SRPT over the last 6 months to buy CIT (move from 43 to 46.70), and missed out on 3 to 45 SRPT....then what kind of favor would we be talking about. Also, SRPT can still go to 60 to 80 IMHO. CIT would have to go to 100...can it do that?
45% drop where they came up with the phrase,"Good money after Bad". Now I get it.
It is currently near its 52 weeek high and HOD. Not chasing a potential buyout. Every board thinks their company is going to be bought out. I'll keep my money here....BTW, have you heard???, SRPT might get bought out.